Tacrolimus-Related Fanconi Syndrome: A Real World Pharmacovigilance Study based on FDA Adverse Event Reporting System (FAERS) Database
Transplantation Proceedings · 2025
DOI: 10.1016/j.transproceed.2025.03.012 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Kun Zhu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Fanconi Syndrome, Immunosuppressive Agents, Pharmacovigilance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Recent case report have highlighted the emergence of Fanconi syndrome as a potentially life-threatening complication linked to tacrolimus. METHODS: We undertook an observational retrospective pharmacovigilance study, leveraging data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database from its inception up to the third quarter of 2023. Our objective was to investigate the potential link between tacrolimus and Fanconi syndrome using statistical methods such as the Information Component (IC) and Reporting Odds Ratio (ROR). All statistical analyses were conducted using R version 3.2.5. FINDING: We identified 39 cases of Fanconi syndrome linked to tacrolimus. The frequency of fanconi syndrome associated with tacrolimus was significantly higher compared to all other drugs in the database (ROR 3.30 [2.40-4.53], IC 1.64[1.17-2.11], Table 2). When comparing to cyclosporine, the signal for tacrolimus-related fanconi syndrome also appears significant (ROR 15.21 [3.68, 62.94], IC 0.73 [0.09-1.37], Table 2). Further analysis revealed that, this signal was only present in the age group of 60 years and older. CONCLUSIONS: Our study has identified a safety signal for tacrolimus in relation to Fanconi syndrome, particularly in individuals aged 60 and above. Additional research is needed to confirm and quantify the risk of tacrolimus-induced Fanconi syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
- Faculty of Synthetic Biology, Shenzhen University of Advanced Technology, Shenzhen 518107, China; Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advance…
Zitieren
APA
Zhu, K., Yang, H., & Zhao, Y. (2025). Tacrolimus-Related Fanconi Syndrome: A Real World Pharmacovigilance Study based on FDA Adverse Event Reporting System (FAERS) Database. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2025.03.012
Vancouver
Zhu K, Yang H, Zhao Y. Tacrolimus-Related Fanconi Syndrome: A Real World Pharmacovigilance Study based on FDA Adverse Event Reporting System (FAERS) Database. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2025.03.012
BibTeX
@article{Zhu2025,
author = {Zhu, Kun and Yang, Hui and Zhao, Yong},
title = {Tacrolimus-Related Fanconi Syndrome: A Real World Pharmacovigilance Study based on FDA Adverse Event Reporting System (FAERS) Database},
journal = {Transplantation Proceedings},
year = {2025},
doi = {10.1016/j.transproceed.2025.03.012}
}
EUVIMED